1. Home
  2. TOL vs INCY Comparison

TOL vs INCY Comparison

Compare TOL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toll Brothers Inc.

TOL

Toll Brothers Inc.

N/A

Current Price

$153.73

Market Cap

12.5B

ML Signal

N/A

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$119.45

Market Cap

23.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOL
INCY
Founded
1967
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5B
23.7B
IPO Year
1994
1994

Fundamental Metrics

Financial Performance
Metric
TOL
INCY
Price
$153.73
$119.45
Analyst Decision
Buy
Buy
Analyst Count
21
28
Target Price
★ $169.11
$130.92
AVG Volume (30 Days)
941.8K
★ 1.9M
Earning Date
12-07-2026
10-29-2026
Dividend Yield
★ 0.67%
N/A
EPS Growth
N/A
★ 4173.33
EPS
★ 7.87
0.50
Revenue
★ $7,143,258,000.00
$3,394,635,000.00
Revenue This Year
N/A
$17.47
Revenue Next Year
$0.82
$4.45
P/E Ratio
★ $20.13
$245.70
Revenue Growth
N/A
★ 13.67
52 Week Low
$123.15
$89.25
52 Week High
$168.36
$132.60

Technical Indicators

Market Signals
Indicator
TOL
INCY
Relative Strength Index (RSI) 63.32 52.76
Support Level $144.44 $119.12
Resistance Level $155.38 $119.29
Average True Range (ATR) 4.75 4.18
MACD 1.91 0.78
Stochastic Oscillator 69.84 63.24

Price Performance

Historical Comparison
TOL
INCY

About TOL Toll Brothers Inc.

Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above that of public competitors. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder in the US based on total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. Its headquarters are in Horsham, Pennsylvania.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Share on Social Networks: